Effects of Heparin and Hirudin on Thrombin Generation and Platelet Aggregation after Intrinsic Activation of Platelet Rich Plasma

Summary

The effects of unfractionated heparin (UH) and recombinant hirudin (rH) on prothrombin activation, free thrombin generation, and platelet aggregation induced by endogenously generated thrombin after intrinsic activation of platelet rich plasma were compared. Free thrombin generation and platelet aggregation were assessed simultaneously by delaying fibrinogen polymerisation with GPRP.

UH more effectively inhibited prothrombin activation and free thrombin generation than rH. Increasing concentrations of rH had hardly any effect on the peak amount of free thrombin, while in the presence of 400 nM UH only traces of free thrombin were detected. Comparison of TAT and THC (thrombin-hirudin complex) generated until the onset of platelet aggregation on a molar basis showed that much more thrombin was inactivated in the presence of rH than in plasma containing UH. The explosive generation of free thrombin in hirudinized plasmas was accompanied by a markedly steeper aggregation curve as compared to heparinized plasmas. The generation of thromboxane B2 was markedly delayed in the presence of UH but not influenced in the presence of rH.

Our results suggest that UH is more effective than rH in inhibiting prothrombin activation after intrinsic activation of platelet rich plasma, while rH prevents clotting more by direct inactivation of already generated thrombin. The inability of even high concentrations of rH to prevent the explosive generation of free thrombin might contribute to the observed inefficiency of rH to inhibit platelet aggregation.

• References

• 1 Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood 1989; 74: 1181-1195
• 2 Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modelled on the carboxy-terminus of hirudin. Blood 1990; 75: 399-406
• 3 Markwardt F. The development of hirudin as an antithrombotic drug. ThrombRes 1994; 74: 1-23
• 4 Glusa E. Hirudin and platelets. Sem Thromb Haemost 1991; 17: 122-125
• 5 Horne III McDonald, Chao E. Heparin binding to resting and activated platelets. Blood 1989; 74: 238-243
• 6 Vermylen JG. Effect of heparin and low molecular weight heparin on platelets. Sem Thromb Haemost 1993; 19: 20-1
• 7 John LC H, Rees GM, Kovacs IB. Inhibition of platelet function by heparin: an etiologic factor in postbypass hemorrhage. J Thorac Cardiovasc Surg 1993; 105: 816-822
• 8 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effects of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
• 9 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4:. Biochem J 1984; 218: 725-732
• 10 Lages B, Weiss HJ. Dependence of human platelet functional responses on divalent cations: Aggregation and secretion in heparin-and hirudin-anti-coagulated platelet-rich plasma and the effects of chelating agents. Thromb Haemost 1981; 45: 173-179
• 11 Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A₂causes feedback amplification involving extensive thromboxane A₂formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987; 70: 647-651
• 12 Gallistl S, Muntean W. Thrombin-hirudin complex formation, thrombin- antithrombin III complex formation, and thrombin generation after intrinsic activation of plasma. Thromb Haemost 1994; 72: 387-392
• 13 Plow EF, Marguerie G. Inhibition of fibrinogen binding to human platelets by the tetrapeptide glycyl-L-prolyl-L-arginyl-L-proline. Proc Natl Acad Sci USA 1982; 79: 3711-3715
• 14 Achyuthan KE, Dobson JV, Greenberg CS. Gly-Pro-Arg-Pro modifies the glutamine residues in the α-and β-chains of fibrinogen: inhibition of transglutaminase cross-linking. Biochim Biophys Acta 1986; 872: 261-268
• 15 Lindhout T, Baruch D, Schoen P, Franssen J, Hemker HC. Thrombin generation and inactivation in the presence of antithrombin III and heparin. Biochemistry 1986; 25: 5962-5969
• 16 Hemker HC, Willems G, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17
• 17 Bichler J, Siebeck M, Maschler R, Pelzer H, Fritz H. Determination of thrombin-hirudin complex in plasma with anenzyme-linked immunosorbent assay. Blood Coagulation and Fibrinolysis 1991; 2: 129-33
• 18 Leis HJ, Hohenester E, Gleispach H, Malle E, Mayer B. Measurement of prostaglandins, thromboxanes and hydroxy fatty acids by stable isotope dilution gas chromatography/mass spectrometry. Biomed Mass Spectrom 1987; 14: 617-621
• 19 Griffith MJ. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. J Biol Chem 1982; 257: 7360-5
• 20 Jesty J. Analysis of the generation and inhibition of activated coagulation factor X in pure systems and in human plasma. J Biol Chem 1986; 261: 8695-8702
• 21 Bèguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-62
• 22 Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-868
• 23 Ofosu FA, Lormeau JC, Craven S, Dewar L, Anvari N. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma. Thromb Haemost 1994; 72: 862-868
• 24 Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. BiochemJ 1987; 243: 579-588
• 25 Bèguin S, Dol F, Hemker HC. Factor IX inhibition contributes to the heparin effect. Thromb Haemost 1991; 66: 306-309
• 26 Bèguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-29
• 27 Yang XJ, Blajchman MA, Craven S, Smith LM, Anvari N, Ofosu FA. Activation of factor V during intrinsic and extrinsic coagulation. Biochem J 1990; 272: 399-406
• 28 Ofosu FA. Prophylactic doses of enoxaparin and heparin inhibit prothrombin activation. Sem Thromb Haemost 1993; 19: 29-30
• 29 Zoldhelyi P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, Chesebro JH. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994; 90: 2671-2678
• 30 Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-388
• 31 Neuhaus KL, v. Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, Doring W, Harmjanz D, Kotter V, Kalhammer E, Simon H, Horacek T. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994; 90: 1638-1642